Condition

Cutaneous Melanoma

ClinicalTrials.gov condition label

Clinical trials23
Recruiting9
Common interventions25
Lead sponsors shown15

Clinical trials

23 shown
Phase 1 Study of PF-08046033 in Advanced Solid TumorsNCT07519655 · 2026-04-08
RECRUITING
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic CancersNCT06967961 · 2025-07-23
RECRUITING
177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsNCT06305962 · 2024-06-03
RECRUITING
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer AgentsNCT06090266 · 2023-10-24
RECRUITING
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)NCT05824975 · 2023-05-30
RECRUITING
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor MalignanciesNCT05669430 · 2023-03-23
RECRUITING
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerNCT05267626 · 2022-04-04
RECRUITING
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy EvaluationNCT05059444 · 2021-09-07
RECRUITING
A Beta-only IL-2 ImmunoTherapY StudyNCT05086692 · 2021-08-27
RECRUITING
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)NCT05520099 · 2023-06-26
ACTIVE_NOT_RECRUITING
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid TumorsNCT05576077 · 2023-01-17
TERMINATED
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid TumorsNCT05571839 · 2023-01-03
TERMINATED
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersNCT05544929 · 2022-10-26
ACTIVE_NOT_RECRUITING
Expression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint InhibitorsNCT04253080 · 2022-04-12
COMPLETED
RTX-224 Monotherapy in Patients With Solid TumorsNCT05219578 · 2022-01-12
TERMINATED
TH1902 in Patients With Advanced Solid TumorsNCT04706962 · 2021-03-04
ACTIVE_NOT_RECRUITING
A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerNCT04254107 · 2020-05-29
TERMINATED
A Study of SGN-CD228A in Advanced Solid TumorsNCT04042480 · 2019-09-03
TERMINATED
MGD019 DART® Protein in Unresectable/Metastatic CancerNCT03761017 · 2018-12-12
COMPLETED
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted VaccineNCT03633110 · 2018-08-29
COMPLETED
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)NCT03767348 · 2017-09-20
ACTIVE_NOT_RECRUITING
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsNCT02791334 · 2016-06-29
COMPLETED
A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope)NCT02831634 · 2016-06-09
COMPLETED

Common interventions

pembrolizumabDRUG4NivolumabDRUG2177Lu-RAD204DRUG1AbemaciclibDRUG1AldesleukinDRUG1AU-007DRUG1AvelumabDRUG1bevacizumabDRUG1Blood sampleBIOLOGICAL1Blood samplingPROCEDURE1brentuximab vedotinDRUG1CemiplimabDRUG1Core Needle Biopsy, Forceps Biopsy, Punch BiopsyPROCEDURE1Cutaneous melanoma biopsyBIOLOGICAL1doxorubicinDRUG1eribulinDRUG1For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:OTHER1GEN-009 Adjuvanted VaccineBIOLOGICAL1GI-102DRUG1GI-102 subcutaneous (SC)DRUG1Guardant RevealDIAGNOSTIC_TEST1GV20-0251BIOLOGICAL1GV20-0251 and Pembrolizumab [KEYTRUDA®]BIOLOGICAL1KFA115DRUG1LorigerlimabBIOLOGICAL1

Trial status mix

RECRUITING9
COMPLETED5
TERMINATED5
ACTIVE_NOT_RECRUITING4

Phase mix

PHASE116
PHASE28
NA3
EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.